Identification of patients with stable coronary artery disease who benefit from ACE inhibitors using Cox mixture model for heterogeneous treatment effects

Van Le, Hollins UniversityFollow

Event Type

Research Presentation

Academic Department

Mathematics and Statistics

Location

VAC Auditorium

Start Date

5-4-2023 5:00 PM

End Date

5-4-2023 5:15 PM

Description

Under the direction of Chirag Nagpal (Ph.D. candidate) and Artur Dubrawski (Ph.D. and faculty), Auton Lab, School of Computer Science, Carnegie Mellon University

The presence of heterogeneity in response to treatment effect is often excluded in the evaluation process of Randomized Clinical Trials. In this talk, we utilize the existing Deep Cox Mixtures with Heterogeneous Effects (CMHE) model to study the heterogeneous treatment effects in The Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) study. The PEACE primary publication found no benefit of using ACE-Inhibitors in patients with stable coronary disease and reduced leftventricular function. With the CMHE to subgroup the PEACE trial population based on response to ACEinhibitors, we identified a patient subgroup whose outcomes could improve with treatment, even though population level on-average analysis shows no desirable effects.

This document is currently not available here.

Share

COinS
 
Apr 5th, 5:00 PM Apr 5th, 5:15 PM

Identification of patients with stable coronary artery disease who benefit from ACE inhibitors using Cox mixture model for heterogeneous treatment effects

VAC Auditorium

Under the direction of Chirag Nagpal (Ph.D. candidate) and Artur Dubrawski (Ph.D. and faculty), Auton Lab, School of Computer Science, Carnegie Mellon University

The presence of heterogeneity in response to treatment effect is often excluded in the evaluation process of Randomized Clinical Trials. In this talk, we utilize the existing Deep Cox Mixtures with Heterogeneous Effects (CMHE) model to study the heterogeneous treatment effects in The Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) study. The PEACE primary publication found no benefit of using ACE-Inhibitors in patients with stable coronary disease and reduced leftventricular function. With the CMHE to subgroup the PEACE trial population based on response to ACEinhibitors, we identified a patient subgroup whose outcomes could improve with treatment, even though population level on-average analysis shows no desirable effects.